Table 3.

Meta-analyses for the prevalence of comorbidities in the study populations of coronavirus disease 2019 cases from China and North America

Comorbidities	China						North America						P 2 value
	Number of cases (n)1	Meta-analysis		Heterogenicity			Number of cases (n)	Meta-analysis		Heterogenicity
		Frequency (%)	95%CI	τ 2	Q	I 2		Frequency (%)	95%CI	τ 2	Q	I 2
Obesity	666	2.1	0.1-4.3	0.001	54	91	26895	22.9	18.1-27.9	0.016	2130	99	< 0.001
Hypertension	22650	25.6	23.8-27.4	0.013	2154	91	34442	47.6	41.0-54.2	0.034	5347	99	< 0.001
Diabetes	23770	11.8	10.9-12.6	0.002	980	79	35384	34.1	30.1-38.2	0.015	3169	98	< 0.001
Cardiovascular diseases	22439	7.9	7.1-8.7	0.002	1339	86	33459	20.8	18.4-23.3	0.005	4379	99	< 0.001
COPD	17263	3.3	2.8-3.7	0.001	540	78	29697	11.6	10.1-13.1	0.001	716	94	< 0.001
Cancer	16527	9.7	7.1-12.2	0.017	19185	99	24564	6.6	5.5-7.6	0.001	254	89	< 0.001
Liver diseases (any)	11087	3.3	2.8-3.9	0.001	276	68	9706	3.1	2.1-4.2	0.001	98	83	0.414
Chronic kidney diseases	16394	2.1	1.7-2.4	0.001	236	59	30761	11.8	10.0-13.6	0.002	1082	86	< 0.001

¹ n is the number of subjects assessed for each comorbidity as per the source database[7].

²Chi Square test for the difference between prevalence of comorbidity in China and North America. COPD: Chronic obstructive pulmonary disease.